MiNK Therapeutics, Inc. (INKT) Insider Trading Activity

NASDAQ$10.79
Market Cap
$55.06M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
592 of 849
Rank in Industry
343 of 491

INKT Insider Trading Activity

INKT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$119,884
6
100

Related Transactions

Ryan Barbaradirector
0
$0
5
$46,619
$-46,619
Buell JenniferChief Executive Officer
0
$0
1
$73,265
$-73,265

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, …

Insider Activity of MiNK Therapeutics, Inc.

Over the last 12 months, insiders at MiNK Therapeutics, Inc. have bought $0 and sold $119,884 worth of MiNK Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at MiNK Therapeutics, Inc. have bought $397,257 and sold $107,367 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 429 shares for transaction amount of $472 was made by AGENUS INC (10 percent owner) on 2023‑10‑16.

List of Insider Buy and Sell Transactions, MiNK Therapeutics, Inc.

2026-10-12SaleBuell JenniferChief Executive Officer
6,938
0.1385%
$10.56
$73,265
-0.47%
2026-06-04SaleRyan Barbaradirector
1,500
0.0301%
$12.76
$19,141
-10.90%
2026-03-10SaleRyan Barbaradirector
1,300
0.0408%
$15.40
$20,017
-16.95%
2026-03-09SaleRyan Barbaradirector
200
0.0042%
$10.17
$2,035
+7.42%
2026-03-02SaleRyan Barbaradirector
100
0.0021%
$10.83
$1,083
+2.66%
2026-02-27SaleRyan Barbaradirector
400
0.0085%
$10.86
$4,343
+2.15%
2023-10-16PurchaseAGENUS INC10 percent owner
429
0.0012%
$1.10
$472
-15.91%
2023-10-13PurchaseAGENUS INC10 percent owner
19,373
0.0561%
$1.10
$21,310
-15.68%
2023-10-12PurchaseAGENUS INC10 percent owner
3,173
0.0089%
$1.10
$3,488
-18.60%
2023-10-04PurchaseAGENUS INC10 percent owner
15,001
0.0465%
$1.09
$16,380
-18.42%
2023-08-29PurchaseAGENUS INC10 percent owner
29,678
0.0826%
$1.52
$45,016
-39.05%
2023-08-28PurchaseAGENUS INC10 percent owner
12,808
0.0371%
$1.45
$18,570
-33.52%
2023-08-24PurchaseAGENUS INC10 percent owner
170,244
0.4482%
$1.54
$262,908
-38.08%
2023-05-11PurchaseAGENUS INC10 percent owner
23,361
0.0606%
$1.43
$33,348
-35.19%
2023-05-10PurchaseAGENUS INC10 percent owner
22,065
0.0649%
$1.51
$33,296
-30.46%
2023-05-05SaleARMEN GARO Hdirector
100,000
0.1767%
$0.95
$94,850
-31.96%
2023-05-05PurchaseAGENUS INC10 percent owner
100,200
0.1772%
$0.95
$95,100
-31.96%
2023-05-05PurchaseAGENUS INC10 percent owner
200
0.0005%
$1.25
$250
-31.96%
2023-05-04PurchaseAGENUS INC10 percent owner
21,473
0.0618%
$1.22
$26,246
-13.60%
2023-05-03PurchaseAGENUS INC10 percent owner
128,689
0.3494%
$1.08
$138,843
-7.26%
Total: 23
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
AGENUS INC10 percent owner
21772863
426.6677%
$234.93M140
<0.0001%
ARMEN GARO Hdirector
1866400
36.5745%
$20.14M11
+23.03%
WIINBERG ULF
281639
5.5191%
$3.04M10
+60.26%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$5,831,763
118
-33.78%
$66.68M
$17,525,882
60
5.22%
$64.7M
$103,288,323
51
4.78%
$56.52M
$24,478,755
37
-34.59%
$53.59M
$115,646,156
35
16.45%
$54.05M

INKT Institutional Investors: Active Positions

Increased Positions9+42.86%65,844+72.11%
Decreased Positions6-28.57%4,945-5.42%
New Positions6New26,203New
Sold Out Positions0Sold Out0Sold Out
Total Postitions24+14.29%152,212+66.69%

INKT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$371.000.67%33,351+9,607+40.46%2025-09-30
Longbow Finance Sa$185.000.33%16,66700%2025-09-30
Renaissance Technologies Llc$162.000.29%14,600+14,600New2025-09-30
Geode Capital Management, Llc$142.000.26%12,806+1,314+11.43%2025-09-30
Blackrock, Inc.$70.000.13%6,298-1,123-15.13%2025-09-30
Ubs Group Ag$63.000.11%5,648+5,364+1,888.73%2025-09-30
Tower Research Capital Llc (Trc)$10.000.02%926+926New2025-09-30
Bank Of America Corp /De/$6.000.01%56800%2025-09-30
Covestor Ltd$1.00<0.01%13100%2025-09-30
Osaic Holdings, Inc.$1.00<0.01%124+4+3.33%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.